Efficacy and safety of risperidone long-acting injection in elderly people with schizophrenia

被引:0
|
作者
Singh, Dhiren [1 ,2 ]
O'Connor, Daniel W. [1 ]
机构
[1] Monash Univ, Dept Psychol Med, Melbourne, Vic 3004, Australia
[2] Peninsula Mental Hlth Serv, Melbourne, Vic, Australia
关键词
risperidone; long-acting injection; old age; efficacy; safety; DIAGNOSTIC-CRITERIA; ANTIPSYCHOTICS; EXPERIENCE; DEMENTIA; RISK;
D O I
暂无
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Antipsychotic medication is the mainstay of treatment in elderly patients with psychosis. In recent years, second generation antipsychotics have come to be preferred. Long-acting risperidone is the first such antipsychotic available for use in this vulnerable group of patients and offers an attractive alternative to traditional medications. The available literature revealed that long-acting risperidone is generally well tolerated and is effective in treating both the positive and negative symptoms of schizophrenia. Despite a lack of randomized trials and head-to-head studies, it appears to be a useful addition to the treatment armory for patients with chronic psychosis who require a depot preparation. Further research into its endocrine and metabolic side effects is needed.
引用
收藏
页码:351 / 355
页数:5
相关论文
共 50 条
  • [21] Efficacy and safety of a novel long-acting risperidone microspheres formulation
    Kane, J
    Eerdekens, M
    Keith, S
    Lesem, M
    Karcher, K
    Lindenmayer, JP
    BIOLOGICAL PSYCHIATRY, 2002, 51 (08) : 167S - 167S
  • [22] Efficacy and safety with long-acting risperidone at medium high doses
    Chinchilla Moreno, A.
    Vega Pinero, M.
    Crespo Hervas, M. D.
    EUROPEAN PSYCHIATRY, 2007, 22 : S109 - S109
  • [23] Symptomatic remission in elderly schizophrenia patients treated with long-acting risperidone
    Tadger, Shelly
    Baruch, Yehuda
    Barak, Yoram
    INTERNATIONAL PSYCHOGERIATRICS, 2008, 20 (06) : 1245 - 1250
  • [24] COST-EFFECTIVENESS ANALYSIS OF OLANZAPINE LONG-ACTING INJECTION COMPARED WITH RISPERIDONE LONG-ACTING INJECTION IN THE TREATMENT OF SCHIZOPHRENIA IN NORWAY
    Carroll, S. M.
    Jemiai, N.
    Suter, B.
    O'Donohoe, P.
    Skjoldborg, U.
    Moller, J.
    Kleivenes, O. K.
    Novick, D.
    VALUE IN HEALTH, 2009, 12 (07) : A358 - A358
  • [25] Efficacy and safety of long-acting risperidone injection after switching from antipsychotics in Chinese patients
    Li, H. F.
    Gu, N. F.
    Zhou, M.
    Jia, F. J.
    Zhao, Z. H.
    Fan, J. X.
    Wang, G.
    Sun, X. L.
    Li, M.
    Zhang, J. B.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2007, 17 : S405 - S406
  • [26] Long-acting risperidone:: Focus on safety
    Mueller, Hans-Juergen
    CLINICAL THERAPEUTICS, 2006, 28 (05) : 633 - 651
  • [27] Pharmacokinetics and tolerability of long-acting risperidone in schizophrenia
    Eerdekens, M
    Van Hove, I
    Remmerie, B
    Mannaert, E
    SCHIZOPHRENIA RESEARCH, 2004, 70 (01) : 91 - 100
  • [28] Long-acting injectable risperidone for the treatment of schizophrenia
    Moeller, Hans-Juergen
    DRUGS, 2007, 67 (11) : 1541 - 1566
  • [29] Paliperidone palmitate versus oral risperidone and risperidone long-acting injection in patients with recently diagnosed schizophrenia: a tolerability and efficacy comparison
    Fu, Dong-Jing
    Bossie, Cynthia A.
    Sliwa, Jennifer K.
    Ma, Yi-Wen
    Alphs, Larry
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2014, 29 (01) : 45 - 55
  • [30] Long-acting risperidone injection improves and maintains quality of life in patients with schizophrenia
    Mehnert, A
    Eerdekens, M
    Fleischhacker, WW
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2003, 13 : S305 - S305